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Objective: Transplant arteriosclerosis (TA) restricts long-term survival of heart transplant recipients.
Although the role of monocyte/macrophages is well established in native atherosclerosis, it has been
studied to a much lesser extent in TA. Plasma cholesterol is the most important non-immunologic risk
factor for development of TA but the underlying mechanisms are largely unknown. We hypothesized that
monocyte/macrophages might play an important role in the pathogenesis of TA under hyperlipidemic
conditions.
Methods:We studied TA in fully mismatched arterial allografts transplanted into hyperlipidemic ApoE/
recipients compared to wild-type controls. The recruitment of distinct monocyte populations into the
grafts was tracked by in vivo labelling with ﬂuorescent microspheres. We used antibody-mediated
depletion protocols to dissect the relative contribution of T lymphocytes and monocytes to disease
development.
Results: In the hyperlipidemic environment the progression of TA was highly exacerbated and the
inﬂammatory CD11bþCD115þLy-6Chi monocytes were preferentially recruited into the neointima. The
number of macrophage-derived foam cells present in the grafts strongly correlated with plasma
cholesterol and disease severity. Depletion of Ly-6Chi monocytes and neutrophils signiﬁcantly inhibited
macrophage accumulation and disease progression. The accelerated monocyte recruitment occurs
through a T cell-independent mechanism, as T cell depletion did not inﬂuence macrophage accumulation
into the grafts.
Conclusions: Our study identiﬁes for the ﬁrst time the involvement of inﬂammatory Ly-6Chi monocytes
into the pathogenesis of TA, particularly in conditions of hyperlipidemia. Targeted therapies modulating
the recruitment and activation of these cells could potentially delay coronary allograft vasculopathy and
improve long-term survival of heart transplant recipients.
 2012 Elsevier Ireland Ltd. Open access under CC BY license.1. Introduction
The development of cardiac allograft vasculopathy or transplant
arteriosclerosis (TA) restricts long-term survival of heart transplantiversity Hospital Malmö, Inga
eden. Tel.: þ46 40 332123;
d Molecular Biology, Univer-
arinescu Str. 38, Targu Mures,
210407.
(A. Schiopu), ovidiucotoi@
der CC BY license.recipients [1,2]. TA is a ﬁbroproliferative disease of the arterial
vasculature, characterised by neointimal hyperplasia due to smooth
muscle cell (SMC) proliferation and accumulation of extracellular
matrix proteins. Unlike the focal atheromas characteristic of native
atherosclerosis, TA lesions are concentric and diffusely spread
throughout the coronary vasculature [3]. The most important
trigger of TA development is the alloimmune-mediated injury of
the graft vasculature, leading to endothelial activation and immune
cell recruitment. Both innate and the adaptive immune mecha-
nisms are involved in the pathogenesis of the disease [4].
Coronary allograft vasculopathy is the second most common
cause of death in long-term survivors of heart transplantation, after
malignancy [5]. Signiﬁcant allograft vasculopathy develops in over
A. Schiopu et al. / Atherosclerosis 223 (2012) 291e29829250% of heart allografts by 10 years after transplantation [5,6] and
rapid initial disease progression is indicative of an increased risk for
early myocardial infarction and mortality [7]. Unfortunately, due to
the diffuse character of the disease, coronary revascularization
procedures are inefﬁcient and do not improve long-term survival
[3].
Post-transplant hyperlipidemia accelerates the development of
TA in cardiac allografts [8e10] and plasma cholesterol was found to
be a strong independent predictor of major adverse cardiac events
in heart transplant recipients [11]. A massive accumulation of lipid-
rich lesions was observed in the coronary arteries of transplanted
human hearts [12]. In animal studies hypercholesterolemia was
associated with accelerated TA development [13e15]. However, the
underlying pathogenic mechanisms linking hyperlipidemia with
enhanced development of TA and the role of the different cellular
populations in this process are largely unknown.
By using fully allogeneic arterial grafts transplanted into nor-
molipidemic wild-type or hyperlipidemic ApoE/ mice we show
that the hyperlipidemic recipients develop severe TA, characterized
by intense foam cell inﬁltration into the neointima. Hyperlipidemia
speciﬁcally enhances the recruitment of the inﬂammatory
CD11bþCD115þLy-6Chi monocyte subset into the grafts and the
macrophage accumulation strongly correlates with plasma
cholesterol and the size of the lesions. Antibody-mediated deple-
tion of Ly-6Chi monocytes and neutrophils decreases intimal
expansion and macrophage inﬁltration, suggesting an active role of
these cells in the pathogenesis of the disease.
2. Materials and methods
Please consult the “Supplementary methods” section for
a detailed description.
2.1. Animals
Sex- and age- matched male and female CBA.Ca (H2k), C57BL/6
(H2b), C57BL/6 ApoE/ (H2b) and C57BL/6 Rag/ (H2b) mice were
used as vessel donors and/or transplant recipients as speciﬁed in
the text.
2.2. Aorta transplantation and tissue analysis
Aortic segments harvested from CBA.Ca mice were transplanted
into fully allogeneic C57BL/6 wild-type (wt) or ApoE/ recipients
by an end-to-end infrarenal interposition technique as previously
described [16]. The mice were fed either a regular mouse diet or
a high fat diet (HFD) containing 21.4% fat and 0.15% supplementary
cholesterol (Dietex International, Witham, UK). The HFD was
initiated 2 weeks before transplantation and continued for the
entire duration of the experiment. The grafts were harvested 21
days after transplantation unless otherwise speciﬁed. For
morphometric analysis, 5 sections from each graft were collected at
200 mm intervals and stained with Miller’s Elastin/van Gieson. The
percentage of the lumen occupied by the neointima, termed intimal
expansion, was calculated as % Intimal expansion ¼ [AI/
(AIþAL)]  100, where AI is the area of the neointima and AL is the
luminal area.
2.3. Immunostaining
Immunohistochemistry and immunoﬂuorescence were per-
formed on 10 mm frozen sections. Oxidized LDL (oxLDL) was
detected as previously described [17] using a recombinant human
IgG1 antibody binding to a speciﬁc ApoB-100 epitope (BioInvent
AB, Lund, Sweden). T cells were stained with biotinylated rat anti-mouse CD4 and CD8 antibodies (eBioscience, Hatﬁeld, UK) and
macrophages with biotinylated rat anti-mouse CD68 (AbD Serotec,
Oxford, UK) or CD11b (eBioscience, Hatﬁeld, UK) antibodies as
speciﬁed in the text. For immunoﬂuorescence, macrophages were
stained using biotinylated anti-mouse CD11b followed by a detec-
tion step with streptavidin-Alexa Fluor 594 (Invitrogen, USA).
Smooth muscle cells were stained with Cy3-conjugated mouse
anti-a actin (Sigma, USA).2.4. In vivo monocyte labelling
The CD11bþCD115þLy-6Clo and the CD11bþCD115þLy-6Chi
monocyte populations were differentially labelled in vivo using
a protocol based on monocyte uptake of green ﬂuorescent latex
FluoresbriteYG microspheres (Polysciences Inc., USA) [18]. The
monocytes were labelled 10 days after transplantation to allow
for neointima development and the mice were sacriﬁced 4 days
later.2.5. Flow-cytometric analysis
Cellular preparations were stained using the following
ﬂuorochrome-conjugated antibodies: CD11b-PE, CD115-APC, CD3-
PECy7, CD4-PB, CD8-PerCP and GR1-biotin followed by
streptavidin-APCCy7 (eBioscience). The signal from the green
ﬂuorescent microspheres was detected in the FITC channel.2.6. Statistics
All statistical analyses were performed using the non-
parametric two-tailed ManneWhitney test. Data are presented as
mean  SEM (standard error of the mean) or as box plots. The
difference between the groups was considered to be statistically
signiﬁcant at P  0.05.3. Experimental results
3.1. Hyperlipidemia accelerates TA
All of the allogeneic aortic grafts transplanted into immuno-
competent mice developed TA, characterized by expansion of the
neointima towards the vascular lumen (Fig. 1AeC). Disease
progression was signiﬁcantly accelerated in the ApoE/ recipients,
both in mice fed regular mouse diet and those fed HFD, compared
to the wt controls. Average TA increased by 100% in the ApoE/
group (33.9  2.4%) and by 250% in the ApoE/HFD group
(59.6  4.9%) compared to the wt control (16.6  4.7%) (Fig. 1E). TA
did not develop in CBA.Ca aortas transplanted into immunodeﬁ-
cient C57BL/6 Rag/ mice (not shown) or in ApoE/ aortas
transplanted into syngeneic ApoE/HFD recipients (Fig. 1D). These
ﬁndings suggest that a competent anti-allogeneic adaptive immune
response is required for the initiation and progression of TA and
that the surgery-associated vascular trauma and hyperlipidemia
alone do not initiate vascular lesions in the graft. The extent of
intimal expansion strongly correlated with plasma levels of total
cholesterol and LDL cholesterol (Fig. 1F and Supplemental table 1).
We have also found a weaker correlation between intimal expan-
sion and plasma triglyceride levels (Supplemental table 1). The
total number of blood monocytes at the time of harvest was
signiﬁcantly elevated in the ApoE/mice kept on HFD for a total of
5 weeks compared with the wt mice and the ApoE/ mice on
a regular diet. The circulating neutrophil numbers did not differ
signiﬁcantly among the three groups (Supplemental table 2).
Fig. 1. Hyperlipidemia accelerates the development of transplant arteriosclerosis (AeC). Representative photomicrographs of fully allogeneic CBA.Ca aortic grafts transplanted into
C57BL/6 recipients: (A) wild-type recipient fed a regular mouse diet (wt); (B) ApoE/ recipient fed a regular mouse diet (ApoE/) and (C) ApoE/ recipient fed a high fat diet
(ApoE/HFD). (D) ApoE/ graft transplanted into a syngeneic ApoE/ recipient on HFD. Elastin/van Giesson stain, the elastic laminae are purple and the cellular cytoplasm is pink.
(E) TA severity in the wt (n ¼ 5), ApoE/ (n ¼ 9) and ApoE/HFD (n ¼ 7) groups, expressed as intimal expansion. (F) Correlation between TA and total plasma cholesterol
(R2 ¼ 0.721, P < 0.0001). * P < 0.05, *** P < 0.001.
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neointima in the ApoE/ recipients
The ORO staining revealed a heavy lipid inﬁltration in aortic
grafts harvested from the ApoE/HFD recipients (Supplemental
Fig. 1B). OxLDL was absent in the neointima but was consistently
found in the innermost layer of the media in the ApoE/HFD
group, indicating the presence of a local pro-oxidative environment
(Supplemental Fig. 1D). No lipid inﬁltration or oxLDL staining were
detected in grafts harvested from wt recipients (Supplemental
Figs. 1A and C).
In the ApoE/HFD mice the CD11bþ foam cells were the domi-
nant inﬁltrating cell type in the grafts and their location coincided
with the lipid deposits (Supplemental Fig. 1F). In the wt group
CD11bþ cells lacked the foam cell appearance and were present
throughout the lesion (Supplemental Fig. 1E). In the wt recipients
neointimawas almost exclusively formed by a thin layer of vascular
SMC (Supplemental Fig. 1G). In contrast, in the ApoE/HFD mice
the SMC formed a thick distinct layer located on the luminal side of
the graft, which appears to be complementary to the foam cell layer
(Supplemental Fig. 1F and H).
3.3. Macrophage accumulation into the grafts correlates with TA
severity
The macrophage content of the lesions, measured as percentage
CD68þ stained area reported to total lesion area, was doubled in theApoE/ mice on normal mouse diet (11.8  2.5%) and more than
tripled in the ApoE/ mice on HFD (22.0  3.8%) compared to the
wt controls (6.3  2.8%) (Fig. 2A and B). We found a highly signif-
icant direct correlation between total plasma cholesterol and the
presence of macrophages in the neointima (R2 ¼ 0.847, P < 0.001)
(Fig. 2C). Furthermore, the intensity of macrophage inﬁltration
strongly correlated with the extent of TA (R2 ¼ 0.751, P < 0.001)
(Fig. 2D).
3.4. T cell recruitment into the allograft is not dependent on
hyperlipidemia and does not correlate with macrophage content
Both CD4þ and CD8þ T cells inﬁltrate the arterial grafts in all
recipients (Supplemental Fig. 2). The Th1 subset of CD4þ T cells and
their secreted cytokine IFNg are major contributors to the devel-
opment of vascular lesions in transplants [4]. In order to determine
whether the accelerated lesion development in the ApoE/mice is
mediated through increased CD4þ T cell recruitment, we counted
the numbers of CD4þ Tcells inﬁltrating the neointima. The absolute
number of CD4þ T cells was signiﬁcantly increased in grafts har-
vested from the ApoE/HFDmice (Fig. 3A). However, there was no
difference between the groups when we reported the number of
CD4þ T cells relative to the size of the lesion, indicating a similar
recruitment rate of these cells into the grafts in the normolipidemic
and the hyperlipidemic environments (Fig. 3B).
In order to test whether the increased monocyte recruitment is
Tcell dependent, we treated a group of ApoE/HFD recipients with
Fig. 2. Macrophage accumulation into the neointima strongly correlates with plasma cholesterol and TA severity. (A) Representative micrographs of macrophage-speciﬁc CD68
staining of arterial allograft sections collected from wt, ApoE/ and ApoE/HFD recipients. (B) Macrophage accumulation in aortic allografts harvested from wt (n ¼ 5), ApoE/
(n ¼ 9) and ApoE/HFD (n¼ 7) hosts, expressed as percentage of the neointimal area. Macrophage recruitment is signiﬁcantly increased in mice with high plasma cholesterol levels
(C) (R2 ¼ 0.847, P < 0.001) and correlates well with disease severity (D) (R2 ¼ 0.751, P < 0.001). ** P < 0.01 *** P < 0.001.
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(YTS 169, 200 mg) antibodies administered i.v. More than 95%
depletion of T cells was achieved within 1 week after injection
(Supplemental Figs. 3A and B). T cell depletion did not signiﬁcantly
inﬂuence the total numbers of circulating monocytes and neutro-
phils in mouse blood (Supplemental Figs. 3C and D). The antibodies
were administered weekly starting at 7 days before trans-
plantation. ApoE/HFD mice receiving 300 mg non-speciﬁc rat IgG
served as the control group. T cell depletion induced a 50% decrease
in lesion size compared to the controls (P < 0.05) (Fig. 3C). The TA
reduction was surprisingly modest considering that the recipient
peripheral T cell pool was maintained at below 5% of the original
size. These data indicate that while a small number of T cells are
sufﬁcient to trigger the development of TA, additional factors play
important roles in the pathogenic process. We found an equal
accumulation of macrophages inside the lesions in the 2 groups
(Fig. 3D), suggesting that the increased macrophage recruitment in
the hyperlipidemic recipients is preferentially governed by T cell-
independent mechanisms.
3.5. Hyperlipidemia accelerates the recruitment of inﬂammatory
Ly-6Chi monocytes into the graft
Monocytes can be functionally divided in 2 main subpopula-
tions: inﬂammatory CD11bþCD115þLy-6Chi (GR1hi) and resident
CD11bþCD115þLy-6Clo (GR1lo) [19]. By using an in vivo protocol
based on monocyte uptake of ﬂuorescent latex microspheres [18]
we differentially labelled the two populations in 2 groups of wt
and 2 groups of ApoE/HFD recipients of CBA.Ca aortic grafts
(Supplemental Fig. 4). The monocytes were labelled 10 days aftertransplantation and the arterial grafts were harvested 4 days later
as the 2 monocyte populations remain distinctly labelled within
this time frame [18].
The ﬂuorescent microspheres were present in the arterial grafts
in all 4 groups of mice at the time of harvest (not shown). Whereas
the Ly-6Clo monocytes were preferentially located under the
endothelium, the inﬂammatory Ly-6Chi monocytes penetrated
deep into the neointima through to the internal elastic lamina
(Fig. 4A and B). Fluorescent anti-CD11b and anti-GR1 counter-
staining of the grafts revealed that the microspheres are mainly
located inside the inﬁltrating CD11bþ and GR1þ cells and that both
microsphereþ and microsphere CD11bþ and GR1þ cells are
present into the neointima (Fig. 4CeF). We quantiﬁed the micro-
sphere content of the neointima as green ﬂuorescent positive area
per total lesion area. Signiﬁcantly more ﬂuorescent microspheres
inﬁltrated the grafts in recipients where the Ly-6Chi monocytes
were labelled compared to their Ly-6Clo counterparts both in
wt (mean  SEM 0.55  0.29% vs. 0.09  0.03%, P < 0.05) and
ApoE/HFDmice (3.23 0.88% vs. 0.29 0.04%, P< 0.01) (Fig. 4G).
The hyperlipidemic environment led to accelerated recruitment of
Ly-6Chi monocytes into the grafts harvested from the ApoE/HFD
mice compared to wt controls (P < 0.05), whereas there was no
signiﬁcant difference regarding Ly-6Clo monocyte inﬁltration
between the two groups (Fig. 4G).
3.6. Depletion of GR1þ inﬂammatory monocytes and neutrophils
decreases TA and intra-graft macrophage accumulation
In order to determine whether the inﬂammatory monocytes
play a pathogenic role in disease progression we treated a group of
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Fig. 3. T cell depletion does not inﬂuence macrophage accumulation into the neointima. Quantiﬁcation of CD4 T cell inﬁltration into allografts harvested from the normolipidemic
wt (n ¼ 5) and hyperlipidemic ApoE/HFD (n ¼ 7) mice expressed as total number of inﬁltrating cells per section (A) and as number of cells reported to the area of the lesion (B).
(C, D) Lesion development and macrophage recruitment in allografts harvested from ApoE/HFD recipients treated with depleting anti-CD4 and anti-CD8 antibodies (n ¼ 6)
compared to a rat IgG control group (n ¼ 6). * P < 0.05, *** P < 0.001. HFD, high fat diet.
A. Schiopu et al. / Atherosclerosis 223 (2012) 291e298 295ApoE/HFD mice receiving CBA.Ca arterial grafts with depleting
rat anti-mouse anti-GR1 antibodies (clone RB6-8C5; 200 mg/injec-
tion) administered i.p. every second day starting at one day before
transplantation. The RB6-8C5 antibody binds both Ly-6C on
monocytes as well as Ly-6G on neutrophils. Our preliminary
experiments showed that the antibody depletes neutrophils and
the Ly-6Chi (GR1hi) monocyte population, conﬁrming previously
published data by Daley et al. [20] (Supplemental Fig. 5). The anti-
GR1 antibody treatment signiﬁcantly decreased intimal expansion
and themacrophage content of the lesions by approximately 35% as
compared with a rat IgG control group (Fig. 5).
4. Discussion
By using a mouse model of arterial transplantation we demon-
strate for the ﬁrst time that the inﬂammatory Ly-6Chi monocytes
are involved in the pathogenesis of TA and that hyperlipidemia
potently accelerates the recruitment of this distinct cellular pop-
ulation into the grafts. Antibody-mediated depletion of Ly-6Chi
monocytes and neutrophils decreases macrophage accumulation
and lesion development, suggesting an active involvement of these
cells in the pathogenesis of the disease. The macrophage-derived
foam cells are a major component of the neointima in hyper-
lipidemic hosts. We found signiﬁcant correlations between plasma
cholesterol, macrophage accumulation and lesion size, suggestingthat the increased Ly-6Chi monocyte recruitment may act as a link
between hypercholesterolemia and the accelerated lesion devel-
opment. Interestingly, this mechanism seems to be independent of
T cell-mediated alloimmunity, as the density of T cells inﬁltrating
the graft remained unchanged in the hyperlipidemic versus the
normolipidemic hosts and T cell depletion did not inﬂuence
macrophage accumulation.
The accelerated TA development in cardiac and vessel allografts
in hyperlipidemic animals was previously shown to be associated
with increased local expression of VCAM-1 and ICAM-1, enhanced
neovascularization and higher levels of TNFa in SMCs [13e15].
Although these studies acknowledged the presence of inﬁltrating
lipids and foam cells, they suggested that the accelerated disease
progression is mediated by increased SMC accumulation into the
neointima [14,15]. Our results do not contradict this hypothesis, as
we have also found a thicker neointimal SMC layer in the arterial
grafts from the ApoE/HFD group compared to wt controls.
However, the strong direct correlation between cholesterol levels,
macrophage inﬁltration and lesion size suggests that monocytes/
macrophages are a major contributor to the enhanced lesion
development in the hyperlipidemic environment. In grafts har-
vested from the ApoE/HFD recipients, the CD68þ immunostained
area accounts for up to 30% of the total size of the lesion but, as the
detection antibody only binds to cellular membrane, the total area
occupied by lipid-loaded foam cells is in fact much larger. In
Fig. 4. Hyperlipidemia accelerates the recruitment of inﬂammatory Ly-6Chi monocytes into the arterial grafts. The ﬂuorescent photomicrographs in (A) and (B) show the presence of
green ﬂuorescent microspheres in arterial allografts harvested from ApoE/HFD mice in which the Ly-6Clo (GR1lo) (A) and the Ly-6Chi (GR1hi) (B) monocytes were labelled. The
latex microspheres were injected 10 days after transplantation and the grafts were harvested 4 days later. Blue is DAPI nuclear stain, the elastic laminae in the media are green
autoﬂuorescent and the white arrows indicate the location of the ﬂuorescent microspheres. (C, D) Red immunoﬂourescent staining of CD11bþ (C) and GR1þ (D) cells in graft sections
from the ApoE/HFD Ly-6Chi group showing inﬁltration of both microsphereþ and microsphere CD11bþ and GR1þ cells into the neointima, with the majority of the latex
microspheres located inside the cells. (D, F) Four times enlargement of the marked areas in (C) and (E) demonstrating the intracellular location of the microspheres. (G) Fluorescent
microsphere inﬁltration into the neointima of allogeneic aortic grafts harvested from 2 groups of wt recipients fed a regular mouse diet and 2 groups of ApoE/HFD recipients in
which the Ly-6Chi and the Ly-6Clo monocytes were differentially labelled (n ¼ 6 mice per group). Microsphere density was quantiﬁed as percentage microsphereþ area per total
lesion area. * P < 0.05, ** P < 0.01. HFD, high fat diet.
Rat IgG Anti-GR1
0
20
40
60
80
100
In
t
im
a
l 
e
x
p
a
n
s
io
n
 
(
%
)
*
Rat IgG Anti-GR1
0
5
10
15
20
25
M
a
c
r
o
p
h
a
g
e
 
in
f
il
t
r
a
t
io
n
 
(
%
)
A B
*
)7=n()6=n()7=n()6=n(
Fig. 5. Depleting anti-GR1 antibody treatment decreases TA development and macrophage accumulation into the neointima (A) Lesion development in CBA.Ca grafts harvested
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A. Schiopu et al. / Atherosclerosis 223 (2012) 291e298 297contrast, macrophages occupy only 6% of the neointima in the
lesions developed in normolipidemic hosts.
Similar to native atherosclerosis, lipid inﬁltration and oxLDL
accumulation inside the vascular wall seems to trigger the
recruitment of monocytes in an attempt to clear the inﬁltrating
lipids from the tissue [21]. We found that the presence of oxLDL is
exclusively conﬁned to the inner layers of the media. This is
a distinctive feature of TA, as in native atherosclerosis the oxLDL-
associated epitopes can be detected throughout the atheroma
[17]. OxLDL is pro-inﬂammatory and immunogenic and has been
shown to trigger accumulation and activation of macrophages, T
cells and SMC [21e23]. It appears that the accelerated foam cell
accumulation and SMC proliferation occur in parallel through local
mechanisms triggered by the increased lipid inﬁltration and
oxidation.
It has previously been suggested that macrophages might be
involved in the pathogenesis of TA, as phagocyte depletion inhibi-
ted development of cardiac allograft vasculopathy in a mouse
model of heart transplantation [24]. We demonstrate that the Ly-
6Chi monocytes are preferentially recruited into the neointima
compared to their Ly-6Clo counterparts both in the normolipidemic
and in the hyperlipidemic hosts and that hyperlipidemia speciﬁ-
cally accelerates this process. Our data extend previous studies by
other groups showing that Ly-6Chi monocytes preferentially
develop into plaque macrophages and dendritic cells in athero-
sclerotic lesions [18,25] and are the main monocyte population
associated with rejection of murine heart allografts [26]. Antibody-
mediated depletion of Ly-6Chi monocytes and neutrophils signiﬁ-
cantly decreased macrophage accumulation and delayed disease
progression. It is difﬁcult to speculate whether these effects are
mainly due to Ly-6Chi monocyte depletion or whether neutrophils
also play a role. The involvement of neutrophils in the pathogenesis
of TA is currently unknown and certainly warrants further inves-
tigation. In the case of native atherosclerosis, recruitment of
inﬂammatory Ly-6Chi monocytes into the atherosclerotic plaques
requires particular chemokineechemokine receptor interactions,
involving CXCR1 in addition to CCR2 and CCR5 [18]. It remains to be
determined whether similar pathways are involved in the recruit-
ment of inﬂammatory monocytes into the arterial grafts. Identi-
fying the key chemokines and chemokine receptors involved in this
process might provide treatment targets for speciﬁcally restricting
the involvement of Ly-6Chi monocytes in the development of
allograft vasculopathy.
T cells play a major role in the pathogenesis of TA. Interestingly,
the density of CD4þ T cells inside the lesions was similar in grafts
harvested from ApoE/HFD mice and wt controls. Treatment ofApoE/HFD recipients with depleting anti T cell antibodies led to
signiﬁcantly smaller lesions compared to controls, but did not
inﬂuence the rate of macrophage accumulation. These observations
suggest that the effect of hyperlipidemia on lesion formation is not
T cell mediated and that the accumulating macrophages do not
accelerate disease by triggering an increased recruitment of T cells
into the graft. Our results are in line with previous ﬁndings
demonstrating that inhibition of macrophage phagocytosis and
antigen-presentation with gadolinium chloride did not delay the
development of coronary allograft vasculopathy in mice [24].
The recruitment of Ly-6Chi monocytes into the neointima in the
ApoE/ mice on a HFD occurs at a much faster pace than that
observed in native atherosclerosis [18], conﬁrming that the path-
ogenesis of TA employs an accelerated inﬂammatory and hyper-
plastic process compared to native atheromas [3]. These ﬁndings
correlate with data from previous experimental and clinical studies
that have demonstrated a much higher accumulation of lipids over
a shorter time period in the coronary arteries of transplanted hearts
compared to native atherosclerosis [12,13]. A potential drawback
of our model is that plasma lipid levels are much higher in the
ApoE/ mice fed a HFD compared to human subjects, and there-
fore we cannot rule out that this might have exacerbated effects on
lesion progression. Additionally, our data and studies by other
groups demonstrate a marked escalation in the total numbers of
circulatingmonocytes in the ApoE/mice fed a HFD, mainly due to
an increase in the Ly-6Chi population [18,25e27]. Consecutively, it
is possible that the increased availability of circulating inﬂamma-
tory monocytes might have contributed to the highly exacerbated
disease progression in the ApoE/HFD group. However, the
correlation between plasma cholesterol levels, macrophage accu-
mulation and the size of the neointima was also valid in the
ApoE/ mice fed a regular mouse diet, which have much lower
lipid levels and similar total and Ly-6Chi monocyte counts as the wt
controls [25]. These observations suggest that the local environ-
ment of the neointima, characterised by intense lipid inﬁltration
and oxidative modiﬁcations, plays an important role in the pref-
erential recruitment of the inﬂammatory monocytes into the
arterial allografts. The histological similarity between the grafts
harvested from the ApoE/ recipients and the appearance of
coronary arteries in necropsy specimens from transplanted human
hearts [12] indicates that this is an accelerated model which might
accurately reﬂect the events that occur at a slower rate in the
clinical setting. We propose the ApoE/ mice as a more appro-
priate recipient strain for studies of transplant-associated vascular
pathology than wt mice, as the wt models do not reﬂect the
hyperlipidemic conditions that often occur in transplant patients.
A. Schiopu et al. / Atherosclerosis 223 (2012) 291e2982985. Conclusions
To our knowledge, this is the ﬁrst report describing the impor-
tant role played by the inﬂammatory Ly-6Chi monocytes in the
pathogenesis of TA. Our data provide a possible mechanistic
explanation for the previously reported correlation between
hyperlipidemia, severe coronary vasculopathy and increased
prevalence of adverse cardiac events in heart transplant recipients
[8e11]. The accumulation of macrophage-derived foam cells into
the arterial allografts occurs independently of T cells and correlates
well with plasma cholesterol levels and the size of the lesions. From
a clinical perspective, our ﬁndings support current guidelines rec-
ommending early post-transplant lipid-lowering therapy. Statins
have been shown to prevent hypercholesterolemia-associated
monocytosis in mice [25] and to delay coronary allograft vascul-
opathy in humans, signiﬁcantly improving survival rates of cardiac
transplant recipients [28]. While the current immunosuppressive
therapies are mainly directed against lymphocyte activation and
proliferation, other cellular populations have largely been over-
looked so far. The ability of the immunosuppressive drug rapamy-
cin to inhibit monocyte inﬁltration into the arterial wall [29] might
partly explain its demonstrated superior efﬁciency compared to
other immunosupressants for the prevention of coronary allograft
vasculopathy [30]. Our study identiﬁes the Ly-6Chi inﬂammatory
monocytes as new potential therapeutic targets for further
improvement of long-term survival in heart transplant recipients.
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